Julia Pugh

Institute of Cancer Research

Papers

1

Total Citations

31

H-Index

1

About

Julia Pugh is a leading clinical researcher in radiation oncology, with a primary focus on prostate cancer treatment and patient quality of life. Her most significant contribution is the landmark PACE-A trial, an international phase 3 randomised controlled trial that directly compared stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer. This work, published in 2023 and already cited 31 times, addresses a critical gap in evidence by providing randomised data on therapeutic equipoise between these two major treatment modalities. Pugh’s research is distinguished by its patient-centered approach, prioritising quality-of-life outcomes alongside oncological efficacy. The PACE-A trial’s primary endpoint analysis has become a cornerstone reference for clinicians and researchers debating optimal treatment strategies for early-stage disease. Her work demonstrates how rigorous trial design can resolve long-standing clinical uncertainties, and her findings are shaping international treatment guidelines. For students and researchers, Pugh exemplifies how translational clinical research can directly impact patient care, balancing survival outcomes with the lived experience of treatment.

Research Focus

Key Achievements

1
H-Index
1
Papers
31
Total Citations
31
Avg Citations/Paper
🏆 Most Cited Paper
PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis.
31 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 18
🏛 Institutions: Institute of Cancer Research

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago